Log in

NASDAQ:MISTMilestone Pharmaceuticals Stock Price, Forecast & News

$3.72
-0.05 (-1.33 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.66
Now: $3.72
$3.91
50-Day Range
$3.13
MA: $3.74
$4.56
52-Week Range
$1.69
Now: $3.72
$24.43
Volume276,521 shs
Average Volume1.50 million shs
Market Capitalization$91.62 million
P/E RatioN/A
Dividend YieldN/A
Beta4.41
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MIST
CUSIPN/A
CIKN/A
Phone514-336-0444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.69 per share

Profitability

Net Income$-55,230,000.00

Miscellaneous

Employees20
Market Cap$91.62 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive MIST News and Ratings via Email

Sign-up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.

Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions

How has Milestone Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Milestone Pharmaceuticals' stock was trading at $19.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MIST stock has decreased by 81.4% and is now trading at $3.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Milestone Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Milestone Pharmaceuticals.

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Milestone Pharmaceuticals.

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) posted its earnings results on Thursday, May, 14th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.07. View Milestone Pharmaceuticals' earnings history.

What price target have analysts set for MIST?

4 analysts have issued twelve-month price objectives for Milestone Pharmaceuticals' shares. Their forecasts range from $3.00 to $32.00. On average, they expect Milestone Pharmaceuticals' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 370.4% from the stock's current price. View analysts' price targets for Milestone Pharmaceuticals.

Has Milestone Pharmaceuticals been receiving favorable news coverage?

Media coverage about MIST stock has been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Milestone Pharmaceuticals earned a news impact score of -2.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days. View the latest news about Milestone Pharmaceuticals.

Are investors shorting Milestone Pharmaceuticals?

Milestone Pharmaceuticals saw a decline in short interest in June. As of June 15th, there was short interest totaling 471,900 shares, a decline of 14.8% from the May 31st total of 553,800 shares. Based on an average trading volume of 1,990,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 3.8% of the company's shares are short sold. View Milestone Pharmaceuticals' Current Options Chain.

Who are some of Milestone Pharmaceuticals' key competitors?

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Allena Pharmaceuticals (ALNA), Opko Health (OPK), AbbVie (ABBV), Walt Disney (DIS), Gilead Sciences (GILD), SCYNEXIS (SCYX), Amplify Energy (AMPY), Amplify Energy (AMPY), Energy Transfer LP Unit (ET) and Menlo Therapeutics (MNLO).

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the following people:
  • Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 51)
  • Dr. Philippe Douville, Founder & Chief Scientific Officer (Age 57)
  • Mr. Timothy L. Maness, VP of Fin. (Age 59)
  • Dr. Francis Plat, Chief Medical Officer (Age 61)
  • Mr. Lorenz Muller, Chief Commercial Officer (Age 55)

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $3.72.

How big of a company is Milestone Pharmaceuticals?

Milestone Pharmaceuticals has a market capitalization of $91.62 million. The company earns $-55,230,000.00 in net income (profit) each year or ($3.50) on an earnings per share basis. Milestone Pharmaceuticals employs 20 workers across the globe.

What is Milestone Pharmaceuticals' official website?

The official website for Milestone Pharmaceuticals is www.milestonepharma.com.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.